Posted February 10 2021, Filed under PR Back to News Home Page

Quay Lends its Expertise to Medicines Discovery Catapult Network

Leading pharmaceutical outsourcing specialist Quay Pharma has become the first CDMO (contract development and manufacturing organisation) to join Medicines Discovery Catapult’s (MDC) Discovery Services Network.

MDC is part of a network of Catapults, a British government initiative established by Innovate UK to support innovation and enable businesses and researchers to collaboratively solve key problems and develop new products and services, taking ideas from concept to reality.

Quay will join over 30 companies who, working alongside the Virtual R&D team at MDC, provide a virtual hub of knowledge and resources for MDC clients, helping to move projects through their various stages to IND submission while providing commercial advice to make each project leaner and more cost-effective.

MDC provides state of the art facilities as well as unrivalled expertise and experience to accelerate innovative drug discovery, in particular helping to overcome challenges that can limit the discovery process. In this way, it also aims to industrialise and drive the introduction of new technologies for the development of new medicines.

Dr Audrey Vardy, Quay’s Head of Business Development – Pre-clinical said: “We are honoured to become part of such an important initiative. The current pandemic has aptly demonstrated the importance of fast and effective drug development without any compromise on standards or processes. The vast array of support provided by MDC’s Discovery Services Network creates the ideal environment for innovative drug development to thrive.”

Quay is recognised as one of the world’s leading CDMOs, offering a complete service through all stages of drug development and clinical supply as well as pre-qualification batches to support Marketing Authorisation applications and initial manufacture of commercial product. In particular, the company’s formulation expertise will be of immense benefit in the early pre-clinical stages of a new project.